MetaCap

Nuvation Bio Inc. Class A (NUVB)

NYSE: NUVBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.80-0.01 (-0.26%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NUVB stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.39
52-week range
3.71 – 9.75
Day range
3.72 – 3.91
Volume / Avg
6.85M / 5.24M
Beta
—

52-week range

$3.71$9.75

NUVB stock today

Nuvation Bio (NUVB) closed at $3.80 on Nov 20, down 0.26% (-$0.01), versus the S&P 500's 3.70% decline. Shares are 61.0% below their 52-week high of $9.75, set on Dec 22, 2025 and 2.4% above the 52-week low of $3.71, near the bottom of the past year's range. NUVB is down 57.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.6%.

Nuvation Bio has posted a net loss over the last twelve months (EPS of -$0.39), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Nuvation Bio

Company profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. David T. Hung M.D.
Headquarters
New York, NY
Employees
310
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Nuvation Bio generated $62.9 million in revenue, up 699.0% from fiscal 2024, its 2nd consecutive year of revenue growth. Nuvation Bio reported a net loss of $204.6 million, compared with a loss of $567.9 million a year earlier. Operating margin was -338.7%.

Nuvation Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$62.90M$7.87M$0——
Growth+698.96%————
Net income$-204.63M$-567.94M$-75.80M$-104.20M$-86.85M
EPS (diluted)$-0.60$-2.11$-0.35$-0.48$-0.44

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$12.45+227.63%

  • Strong buy 3
  • Buy 9
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $7.00High $21.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.16 vs $-0.11
Surprise
-45.45%

NUVB news

All NUVB news

Nuvation Bio peers

Health Care sector
NUVB peer companies
CompanyPrice% ChgMarket capCompare
NBTXNanobiotix S.A. ADR26.50-2.98%$1.35Bvs NUVB
PAHCPhibro Animal Health Corporation Class A33.29-2.32%$1.35Bvs NUVB
URGNUroGen Pharma Ltd.27.65-12.86%$1.36Bvs NUVB
QUREuniQure N.V.19.35-4.35%$1.36Bvs NUVB
RAPPRapport Therapeutics Inc.23.16-1.82%$1.37Bvs NUVB
INVAInnoviva Inc.18.410.00%$1.31Bvs NUVB
ANABAnaptysBio Inc.46.63-1.62%$1.39Bvs NUVB
TYRATyra Biosciences Inc.20.12+1.98%$1.39Bvs NUVB

Indexes, lists and sector

Nuvation Bio stock FAQ

What is Nuvation Bio's stock price today?

NUVB last traded at $3.80 as of Nov 20, 4:00 PM EST, down 0.26% on the day. Prices are delayed at least 15 minutes.

Who is Nuvation Bio's CEO?

Dr. David T. Hung M.D. is the chief executive officer of Nuvation Bio Inc. Class A, which has about 310 employees.

What is the NUVB 52-week high?

The 52-week high for NUVB is $9.75 and the 52-week low is $3.71. The stock is currently 61.0% below its high.

Compare NUVB